Cargando…
Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole
BACKGROUND: Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) ar...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862958/ https://www.ncbi.nlm.nih.gov/pubmed/19582579 http://dx.doi.org/10.1007/s10620-009-0871-8 |
_version_ | 1782180739720151040 |
---|---|
author | Kovacs, Thomas O. Freston, James W. Haber, Marian M. Atkinson, Stuart Hunt, Barbara Peura, David A. |
author_facet | Kovacs, Thomas O. Freston, James W. Haber, Marian M. Atkinson, Stuart Hunt, Barbara Peura, David A. |
author_sort | Kovacs, Thomas O. |
collection | PubMed |
description | BACKGROUND: Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) are limited. AIMS: To investigate QOL in subjects with healed EE who received 12 months of double-blind maintenance treatment with lansoprazole or ranitidine, followed by long-term open-label lansoprazole therapy to prevent recurrence of EE. METHODS: Subjects with healed EE received 12 months of double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily, followed by dose-titrated, open-label lansoprazole therapy for up to 82 months. RESULTS: During double-blind treatment (n = 206), lansoprazole-treated patients showed significantly (P ≤ 0.05) greater improvements than ranitidine-treated patients in the frequency, severity, and ‘bothersomeness’ of heartburn, the symptom index, problems of activity limitation, eating and drinking problems, symptom problems, health distress, and social functioning. During dose-titrated, open-label treatment (n = 195), all disease-specific QOL scales except sleep improved significantly (P < 0.001) from open-label baseline at each time-point. CONCLUSIONS: Maintenance treatment with lansoprazole for 12 months in healed EE subjects produced significantly greater improvements in QOL indicators than ranitidine. These improvements were sustained during dose-titrated, open-label lansoprazole treatment. |
format | Text |
id | pubmed-2862958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-28629582010-05-04 Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole Kovacs, Thomas O. Freston, James W. Haber, Marian M. Atkinson, Stuart Hunt, Barbara Peura, David A. Dig Dis Sci Original Article BACKGROUND: Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) are limited. AIMS: To investigate QOL in subjects with healed EE who received 12 months of double-blind maintenance treatment with lansoprazole or ranitidine, followed by long-term open-label lansoprazole therapy to prevent recurrence of EE. METHODS: Subjects with healed EE received 12 months of double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily, followed by dose-titrated, open-label lansoprazole therapy for up to 82 months. RESULTS: During double-blind treatment (n = 206), lansoprazole-treated patients showed significantly (P ≤ 0.05) greater improvements than ranitidine-treated patients in the frequency, severity, and ‘bothersomeness’ of heartburn, the symptom index, problems of activity limitation, eating and drinking problems, symptom problems, health distress, and social functioning. During dose-titrated, open-label treatment (n = 195), all disease-specific QOL scales except sleep improved significantly (P < 0.001) from open-label baseline at each time-point. CONCLUSIONS: Maintenance treatment with lansoprazole for 12 months in healed EE subjects produced significantly greater improvements in QOL indicators than ranitidine. These improvements were sustained during dose-titrated, open-label lansoprazole treatment. Springer US 2009-07-07 2010 /pmc/articles/PMC2862958/ /pubmed/19582579 http://dx.doi.org/10.1007/s10620-009-0871-8 Text en © The Author(s) 2009 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article Kovacs, Thomas O. Freston, James W. Haber, Marian M. Atkinson, Stuart Hunt, Barbara Peura, David A. Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole |
title | Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole |
title_full | Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole |
title_fullStr | Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole |
title_full_unstemmed | Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole |
title_short | Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole |
title_sort | long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862958/ https://www.ncbi.nlm.nih.gov/pubmed/19582579 http://dx.doi.org/10.1007/s10620-009-0871-8 |
work_keys_str_mv | AT kovacsthomaso longtermqualityoflifeimprovementinsubjectswithhealederosiveesophagitistreatmentwithlansoprazole AT frestonjamesw longtermqualityoflifeimprovementinsubjectswithhealederosiveesophagitistreatmentwithlansoprazole AT habermarianm longtermqualityoflifeimprovementinsubjectswithhealederosiveesophagitistreatmentwithlansoprazole AT atkinsonstuart longtermqualityoflifeimprovementinsubjectswithhealederosiveesophagitistreatmentwithlansoprazole AT huntbarbara longtermqualityoflifeimprovementinsubjectswithhealederosiveesophagitistreatmentwithlansoprazole AT peuradavida longtermqualityoflifeimprovementinsubjectswithhealederosiveesophagitistreatmentwithlansoprazole |